Verdict: Side-by-side breakdown using the Bull Rankings model. QGEN scored 55.9, RMD scored 75.9 — RMD leads.
Compare another set
Different reporting periods. RMD's fundamentals are as of June 2026, but QGEN's are as of December 2025 — a 6-month gap. Growth, margin and valuation figures below therefore describe different windows and aren't strictly like-for-like.
QGEN
Qiagen N.V.
Diagnostics & Research · Quality-Growth
55.9
$45.38 · $9.4B
fundamentals as of
Score gap
20.0
RMD leads
RMD
ResMed Inc.
Medical Instruments & Supplies · Quality-Growth
75.9
$230.05 · $32.4B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
CheapestRMD22.1x
Fastest growthRMD+9.9%
Strongest balance sheetRMD0.13
Highest qualityRMD90 / 100
Largest discount to fair valueQGEN-8%
Side by side · every name on one set of axes
Growth against the P/E multiple. Up and to the right is cheaper and faster — the quality-growth idea in one picture. Points beyond the axis are pinned to the edge and marked off-scale rather than allowed to compress everything else.
The model, pillar by pillar (0–100 each)
QGEN
stronger →← stronger
RMD
64
Qualityreturns · margins · balance sheet
90
49
Growthrevenue & earnings expansion
72
56
Valuevaluation vs sector peers
68
RMD is stronger on 3 of 3 pillars.
Fundamentals, head-to-head
QGEN
RMD
$453mC
FCF
$1.6bC+
+5.7%C+
Rev
+9.9%B
0.49B
D/E
0.13B+
23.0xB+
P/E
22.1xB+
1.19B+
PEG
1.32B
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
QGEN
RMD
8% below
Price vs fair valuelower is cheaper
7% below
~3%/yr
Growth the price impliesyr-1 FCF growth, fading to 4% · lower = less priced in
~5%/yr
+6%
1-yr DCF upside
0%
+8%
5-yr DCF upside
+8%
+13%
10-yr DCF upside
+21%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
QGEN
Why this score
Buying back stock
RMD
Why this score
Raising its dividend
Durable high returns
The companies
QGENQiagen N.V.
Diagnostics & Research · $45.38 · beta 0.61
Why now
Diagnostics & Research · market cap $9.4b. Down 22% from 52-week high of $57.82 — deep drawdown territory. 15 sell-side analysts rate this a Buy with a mean 1-yr target of $47.80 (implying +5% upside).
Moat
Net margin 20% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 11% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. FCF converts 107% of net income — earnings translate cleanly into cash.
Risk
Mature compounder — the risk is paying up for quality at a moment when growth is decelerating. Watch for sequential revenue + margin trends; the inflection from "compounder" to "ex-compounder" is hard to spot until the multiple already started compressing.
RMDResMed Inc.
Medical Instruments & Supplies · $230.05 · beta 0.75
Why now
Medical Instruments & Supplies · market cap $32.4b. 17% off the 52-week high of $277.67. 17 sell-side analysts rate this a Buy with a mean 1-yr target of $250.22 (implying +9% upside).
Moat
Net margin 27% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 23% is above 15% — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 108% of net income — earnings translate cleanly into cash.
Risk
Mature compounder — the risk is paying up for quality at a moment when growth is decelerating. Watch for sequential revenue + margin trends; the inflection from "compounder" to "ex-compounder" is hard to spot until the multiple already started compressing.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where QGEN and RMD diverge
On the headline score the gap is 20.0 points in favor of RMD. The widest single difference is Quality, where RMD leads by 26.7 points.
QualityQGEN 63.5 · RMD 90.2RMD +26.7
GrowthQGEN 49.4 · RMD 71.8RMD +22.4
ValueQGEN 55.7 · RMD 67.6RMD +11.9
Pillars run 0–100. Value is judged against each company's own sector, so a Value score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.
Common questions
Is RMD or QGEN the better stock?
RMD scores higher: RMD 75.9, QGEN 55.9 out of 100 on the Bull Rankings quality-growth score, which blends business quality, growth and valuation into one number. A higher score means a stronger business at a more reasonable price — it is not a price target or a recommendation.
Where do RMD and QGEN differ most?
The widest gap is quality, where RMD leads by 27 points on the 0–100 pillar scale. RMD leads all three pillars, so the gap is broad rather than a single-measure difference.
How are RMD and QGEN scored?
Each carries the same 0–100 quality-growth score used everywhere on the site, built from three pillars — quality (profitability and returns on capital), growth (revenue and earnings), and value (what you pay for them) — combined as a geometric mean, so a weak pillar cannot be papered over by a strong one.
How current is this comparison?
The whole universe is re-scored every trading day after the US market close, so the scores and fundamentals here reflect the latest published edition.